Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.

TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.

The research represents a major step forward in revealing how the three dimensional form of DNA shapes the way human biology functions. In a major step toward understanding how the physical form of ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing incidence and extremely ...

Artificial intelligence has just redrawn the map of our genome’s control room, revealing hundreds of thousands of tiny DNA ...

In scientific research, peptides play a pivotal role across a wide range of studies, from drug development to molecular ...

Projects include genomic monitoring of PRRSV recombination following therapeutic vaccination, genomic characterization of ...